09 January 2025
ImmuPharma
PLC
("ImmuPharma" or the "Company")
Immupharma Announces
Breakthrough Findings into Autoimmune Diseases
ImmuPharma PLC (LSE:IMM), the
specialist drug discovery and development company, announces
innovative groundbreaking advancements in its preclinical research
program focused on P140 and the pathogenesis of autoimmune
diseases. This new discovery, conducted by the Company's R&D
subsidiary ImmuPharma Biotech, has yielded data that provides novel
insights into autoimmune disease mechanisms.
Importantly for our autoimmune
therapy P140, especially for our lead indication in SLE, these
findings pave the way for:
·
Earlier and more accurate
diagnostics
·
Identifying patients most
likely to respond to P140 therapy
·
Improved monitoring of the
patient's response to treatment with P140
Through this research, the company
is making a significant step towards personalised medicine in SLE
and other autoimmune diseases.
The Company is not at this time
releasing detailed data as these findings form part of the ongoing
expansion of our intellectual property portfolio including
additional patents for P140.
Commenting on this announcement, Tim
McCarthy, CEO of ImmuPharma said: "We are
delighted to share these significant findings from ImmuPharma
Biotech. This breakthrough research confirms our confidence in
P140, its future therapeutic success and also creates potential new
opportunities to strengthen our intellectual property portfolio,
positioning us at the forefront of innovation in autoimmune disease
therapies."
Commenting on this announcement,
Sébastien Goudreau, CEO of ImmuPharma Biotech said:
"The findings we have announced today highlight
the extremely diligent and focused research we have been conducting
behind the scenes at Immupharma Biotech in order to better
characterise and explain our lead asset P140 and its
application in autoimmune diseases,
which is now gaining significant attention within the
biopharmaceutical industry."
Ends
This announcement contains inside information as stipulated
under the UK version of the Market Abuse Regulation no 596/2014
which is part of English law by virtue of the European (withdrawal)
Act 2018, as amended. On publication of this announcement via
a regulatory information service, this information is considered to
be in the public domain.
|
For further information please
contact:
|
ImmuPharma PLC (www.immupharma.co.uk)
Tim McCarthy, Chief Executive
Officer
Lisa Baderoon, Head of Investor
Relations
|
+44 (0) 207 206 2650
+ 44 (0) 7721 413496
|
|
|
|
|
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker)
Patrick Claridge, Bob
Pountney
SI
Capital (Joint Broker)
Nick Emerson
|
+44 (0) 203
368
3550
+44 (0) 20 3650 3650
+44 (0) 1483 413500
|
|
|
|
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases and anti-infectives.
The lead program, P140, is a unique non-immunosuppressive peptide
for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP
(Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical
models suggest therapeutic activity for many other autoimmune
diseases.
About Lupus (Systemic Lupus Erythematosus /
SLE)
Lupus is a chronic inflammatory
disease which is thought to affect some 16 million individuals
worldwide. The current standard of care still consists of steroid
and anti-malarial therapies which have side-effects and poor
response in many patients. Recently more targeted monoclonal
therapies are GlaxoSmithKline's Benlysta and more recently,
AstraZeneca's Saphnelo. There still exists a high unmet medical
need for a drug that has a strong efficacy and safety
profile.
For additional information about
ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity
Identifier) code : 213800VZKGHXC7VUS895.
